Mochi Health Semaglutide Review: Clinician Network Model and 2026 Pricing

What is documented about compounded semaglutide

FDA's period of enforcement discretion for compounded semaglutide injection has ended. For state-licensed pharmacies and physicians it ended after a court denied the compounders' injunction request on 2025-04-24, and for outsourcing facilities FDA set 2025-05-22 as the end date [2].

A pharmacy may compound semaglutide for an individual patient on a prescription, and a product that is essentially a copy of an approved drug is allowed only if it is made rarely (FDA says it does not intend to act against four or fewer such prescriptions per calendar month) or if the prescriber documents a significant difference for that patient [2]. Adding another ingredient does not settle the question on its own: FDA says a semaglutide-plus-vitamin-B12 product may still be essentially a copy when the route is the same and each strength is within 10% of the commercial product [2]. Semaglutide is not on the outsourcing facility bulks list, and on 2026-04-30 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from that list, with comments due 2026-06-29 and no final decision made [2][6].

FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing. By 2026-05-31 it had received 990 adverse event reports for compounded semaglutide [1]. FDA reports dosing errors with compounded injectable semaglutide (patients measuring the wrong dose, clinicians miscalculating, doses above the labeled dose), and says semaglutide sodium and semaglutide acetate salts are different active ingredients from the approved drug, with no lawful basis for compounding that it is aware of [1].

What FDA says to look for in a telehealth seller

FDA's page on unapproved GLP-1 drugs says patients should get a prescription from their doctor and fill it at a state-licensed pharmacy [1]. Its telehealth red flags include a company that does not require a screening and prescription by a licensed doctor before providing medicine, has no licensed doctor available to answer questions after you receive the medication, sends medicine that looks different from what was pictured or arrives damaged or without instructions for use, or puts spelling errors, an incorrect pharmacy address or a possibly fraudulent pharmacy name on the label [1]. A company that claims a compounded drug is the same as an FDA-approved drug is also on the list [1].

What the approved weight-management versions contain

Wegovy injection is approved to reduce excess body weight and maintain the loss in adults and in children aged 12 and older with obesity, and in adults with overweight plus a weight-related condition, and to reduce major cardiovascular event risk in adults with established cardiovascular disease and obesity or overweight [3]. Wegovy tablets (1.5, 4, 9 and 25 mg) were approved 2025-12-22 for adults [4].

Under the label, the injection starts at 0.25 mg weekly for 4 weeks, steps through 0.5, 1 and 1.7 mg, and reaches 2.4 mg maintenance from week 17; adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go to 7.2 mg weekly [3].

In the 2.4 mg weight-management trials, nausea occurred in 44% vs 16% on placebo, diarrhea 30% vs 16%, vomiting 24% vs 6% and constipation 24% vs 11%; any gastrointestinal reaction 73% vs 47%; 6.8% vs 3.2% stopped treatment because of an adverse reaction [3]. The boxed warning describes thyroid C-cell tumors in rodents, says whether this happens in humans is unknown, and contraindicates the drug in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [3]. The label says to stop at least 2 months before a planned pregnancy because of the long half-life [3].

What the weight-loss trial measured

STEP 1 randomized 1,961 adults with obesity, or overweight plus a weight-related condition, and no diabetes to semaglutide 2.4 mg weekly or placebo for 68 weeks: mean weight change -14.9% vs -2.4% [5]. That trial tested the approved product, not compounded versions.